Compare Novo Nordisk A/S (NVO) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs PepsiCo, Inc. — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while PepsiCo, Inc. trades at $135 (market cap $184.89B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and PepsiCo, Inc. pays the higher dividend (4.37%). Which is the better fit depends on your goals.
| NVO | PEP | |
|---|---|---|
Market Cap | $220.53B | $184.89B |
Sector | Health | Consumer Staples |
52-Week High | $71.70 | $170.44 |
52-Week Low | $35.29 | $135.40 |
Enterprise Value | $239.49B | $227.39B |
Dividend Yield | 3.63% | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PepsiCo (PEP) trades at $134.98, down 1.56% today, with a bearish technical signal as moving averages indicate selling pressure. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $93.93B in 2025, though net income margin dipped to 8.77%. Analysts maintain a consensus price target of $158.50, implying upside, while recent news highlights price cuts on snacks to address consumer pushback on high costs.
The outlook for PEP is mixed; strong cash flow and dividend payments support income investors, but margin pressure and competitive risks persist. Upside depends on North American performance recovery and effective pricing strategy execution. Key risks include consumer sensitivity to price hikes and macroeconomic headwinds affecting discretionary spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
